Urine toxicology as an outcome measure in drug abuse clinical trials: Must every sample be analyzed?

Journal of Addictive Diseases

Volumn 15, Issue 2, 1996, Pages 85-92

  Compton, Peggy A ^a,b   Ling, Walter ^a,c   Wesson, Donald R ^a   Charuvastra, V Charles ^a   Wilkins, Jeff ^c  

^a Los Angeles Addict Treatm Res C   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; URINALYSIS;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; SUBSTANCE-RELATED DISORDERS;

EID: 0029922203     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v15n02_07     Document Type: Article

References (13)

1. Batki SL, Manfredi LB, Jacob P, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: Quantitative plasma and urine cocaine/benzoyl-ecgonine concentrations. J Clin Psychopharm. 1993;13:243-250.
2. Jain RB, Open/panel discussion: Design issues. In: Jain RB, ed. Statistical Issues in Clinical Trials for Treatment of Opiate Dependence. NIDA Research Monograph 128. DHHS Pub. No, (ADM)92-1947. Washington, DC:U.S. Govt. Print. Office, 1992: 64-69.
3. Tai B. Clinical decision network of cocaine addiction pharmacotherapy. Workshop II: Outcome measures and efficacy criteria. Summary Report, NIH NIDA MDD, Bethesda, 1993.
4. Tennant F. Quantitative urine levels of abusable drugs for clinical purposes. Clinic Lab Med. 1990; 10:301-309.
5. Cone EJ, Dickerson SL. Efficacy of urinalysis in monitoring heroin and cocaine abuse patterns: Implications in clinical trials for treatment of drug dependence. In: Jain RB, ed. Statistical Issues in Clinical Trials for Treatment of Opiate Dependence. NIDA Research Monograph 128. DHHS Pub. No. (ADM)92-1947. Washington, DC: U.S. Govt. Print. Office, 1992: 46-58.
6. Jain RB. Design of clinical trials for treatment of opiate dependence: What is missing? In: Jain RB, ed. Statistical Issues in Clinical Trials for Treatment of Opiate Dependence. NIDA Research Monograph 128. DHHS Pub. No. (ADM)92-1947. Washington, DC: U.S. Govt. Print. Office, 1992: 29-36.
7. DeAngelis GG. Testing and Screening for Drugs of Abuse. New York: Marcel Dekker, Inc., 1976.
8. Goldstein A, Brown BW. Urine testing schedules in methadone maintenance treatment of heroin addiction. JAMA 1970; 214:311-315.
9. Harford RJ, Kleber HD. Comparative validity of random-interval and fixed-interval urinalysis schedules. Arch Gen Psychiat. 1978; 35:356-359.
10. Manno JE. Specimen collection and handling. In: Hawks RL, Chiang CN, eds. Urine Testing for Drugs of Abuse. NIDA Research Monograph 73. DHHS Pub. No. (ADM)87-1481. Washington, DC: U.S. Govt. Print. Office, 1986: 24-29.
11. Council on Scientific Affairs. Scientific issues in drug testing. JAMA, 1987; 257:3110-3114.
12. Verebey K. Diagnostic laboratory: Screening for drug abuse. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins, 1992: 425-436.
13. Ling W, Wesson DR, Charuvastra VC, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance. Arch Gen Psychiat, in press.